M. Schollenberger

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis

Ami A. Shah, E. Lipson, V. Anagnostou, 2021, RMD Open.

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

J. Taube, E. Lipson, W. Sharfman, 2017, Journal of Immunotherapy for Cancer.

Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration

E. Lipson, D. Brennan, A. Rosenberg, 2021, Transplantation direct.

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma

Daniel Q. Sun, E. Lipson, N. Aygun, 2020, Journal for ImmunoTherapy of Cancer.

Kidney retransplantation after anti–programmed cell death‐1 (PD‐1)–related allograft rejection

E. Lipson, D. Pardoll, D. Brennan, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Ami A. Shah, E. Lipson, J. Naidoo, 2019, Annals of the rheumatic diseases.

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

E. Lipson, J. LoPiccolo, W. Sharfman, 2019, Journal of Immunotherapy for Cancer.

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

E. Lipson, W. Sharfman, K. Bleich, 2018, Molecular oncology.